lactate dehydrogenase A inhibitors (Ryvu Therapeutics/Merck KGaA)

N/A

Report date: 2025/03/20 16:13:13
NME

Base Information

Drug Namelactate dehydrogenase A inhibitors (Ryvu Therapeutics/Merck KGaA)
Drug Alias Namelactate dehydrogenase A inhibitors (Selvita/Merck KGaA)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionL-lactate dehydrogenase A chain degraders
TargetsL-lactate dehydrogenase A chain
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryPolandGermany
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesRyvu Therapeutics Sa
China Registration ClassN/A

Develop Information

Active CompaniesRyvu Therapeutics SaJagiellonian University, KrakowMerck KGaA, Darmstadt, Germany
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A